

# INFORMATION DISCLOSURE CITATION

SUPPLEMENTAL

Docket No.: RLL-256.2CIPUS

Serial No.: 10/552,503

Applicants: MEHTA et al.

Filed: 6/8/2006

Group: 1614

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/G.S./	S2A1	2006/0247225	11/2/2006	Mehta et al.	514	213.01	
	S2A2	2006/0287380	12/21/2006	Salman et al.	514	412	
	S2A3	2006/0281805	12/14/2006	Mehta et al.	514	412	
	S2A4	2007/0010568	1/11/2007	Mehta et al.	514	412	
	S2A5	2007/0135508	6/14/2007	Mehta et al.	514	412	
	S2A6	7,288,562	10/30/2007	Mehta et al.	514	412	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES   NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/G.S./	S2C1	Wess et al., "Muscarinic receptor subtypes mediating central and peripheral antinociception studied with muscarinic receptor knockout mice: A review", <i>Life Sciences</i> , 72:2047-2054 (2003)
	S2C2	O'Neill, "Unusual suspect for antipsychotic-induced diabetes", <i>Drug Discovery Today</i> , 10(20):1338 (2005)
	S2C3	Michel and Hegde, "Treatment of the overactive bladder syndrome with muscarinic receptor antagonists - a matter of metabolites?", <i>Naunyn-Schmiedeberg's Arch Pharmacol</i> , 374:79-85 (2006)
	S2C4	Latifpour et al., "Effects of Experimental Diabetes on Biochemical and Functional Characteristics of Bladder Muscarinic Receptors", <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 248(1):81-88 (1989)
	S2C5	Carrier and Aronstam, "Altered Muscarinic Receptor Properties and Function in the Heart in Diabetes", <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 242(2):531-535 (1987)
	S2C6	Ahrén et al., "Blockade of muscarinic transmission increases the frequency of diabetes after low-dose alloxan challenge in the mouse", <i>Diabetologia</i> , 39:383-390 (1996)
	S2C7	Abrams et al., "Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder", <i>British Journal of Pharmacology</i> , 148(5):565-578 (2006)

EXAMINER /Golam Shameem/

DATE CONSIDERED 02/02/2009

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.